(PRWEB) May 22, 2013

Pretrial proceedings for federal DePuy Pinnacle lawsuits are progressing. On May 15 a judge for the Pinnacle multidistrict litigation ordered Johnson & Johnson’s DePuy Orthopaedics unit to produce monitoring reports related to a federal investigation into the company’s medical device sales practices, according to court documents. The Rottenstein Law Group LLP, a DePuy Pinnacle law firm, maintains http://www.pinnaclelawsuit.com, which has more information on the metal-on-metal hip implant and how to file a lawsuit if appropriate.

Plaintiffs’ lawyers filed the motion to compel the release of the monitoring reports for use in the lawsuits pending in federal courts, according to court documents (In re: DePuy Orthopaedics Inc. Pinnacle Hip Implant Product Liability Litigation; MDL-2244, U.S. District Court for the Northern District of Texas). A 2007 agreement and the monitoring reports were the result of a U.S. Attorney’s office’s criminal investigation into allegations that DePuy offered kickbacks to surgeons to use its hip replacement products.

Read more: DePuy Pinnacle Lawsuit Update: Federal Court Orders DePuy to Produce Data from Sales Practices Investigation, Rottenstein Law Group LLP Reports

The post DePuy Pinnacle Lawsuit Update: Federal Court Orders DePuy to Produce Data from Sales Practices Investigation, Rottenstein Law Group LLP Reports appeared first on Oregon Capitol News.

The judge overseeing pretrial proceedings in the federal consolidation of Mirena IUD lawsuits has called specifically for female lawyers to be included in a plaintiffs’ leadership committee, according to Reuters.* The Rottenstein Law Group LLP acknowledges the judge’s request, noting that its lawyers can help with Mirena lawsuits by providing information on Mirena side effects and how to file a lawsuit.

Judge Cathy Seibel called for the addition of some female lawyers to the committee. This followed requests from at least one plaintiff’s attorney that women be represented on the committee because, according to Reuters, “female attorneys could relate to [plaintiffs’] challenges and promote that empathy to a judge or jury.”

Read full story at PRWeb.com: Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP

The post Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP appeared first on Oregon Capitol News.

(PRWEB) May 17, 2013

Johnson & Johnson subsidiary DePuy Orthopaedics announced on May 16 that it will stop sales of metal-on-metal hip replacements. This comes after the company saw the market for the products drop significantly* amid lawsuits and calls for increased regulation,** and after the 2010 recall of the DePuy ASR hip implant. The Rottenstein Law Group LLP, a metal-on-metal hip implant law firm, applauds the decision to remove these products from the market and notes that it maintains a comprehensive website at http://www.hipreplacementlawsuitcenter.com with information on the metal-on-metal hip products from a variety of companies facing increased scrutiny.

Johnson & Johnson said its decision to stop selling the metal liners in the Ultamet Metal-on-Metal Articulation and Complete Ceramic-on-Metal Acetabular Hip System was because of decreased demand and not because of the safety concerns cited by the FDA regarding metal-on-metal hips or the more than 10,000 lawsuits pending against DePuy over the ASR hip implant system (In re: DePuy Orthopaedics Inc., ASR Hip Implant Products Liability Litigation, MDL-2197 (U.S. District Court for the Northern District of Ohio)), according to a May 16 Bloomberg report. The company will continue to sell its DePuy Pinnacle system, though.

Read full story at PRWeb.com: DePuy Announces It Will Stop Selling Metal-On-Metal Hip Implants, Notes Rottenstein Law Group LLP

The post DePuy Announces It Will Stop Selling Metal-On-Metal Hip Implants, Notes Rottenstein Law Group LLP appeared first on Oregon Capitol News.

The Rottenstein Law Group LLP, a New York-based law firm that represents hundreds of plaintiffs in transvaginal mesh lawsuits, acknowledges a study comparing the results of pelvic prolapse repair using vaginal mesh and native tissue.

The results of a prospective randomized trial, which were reported by Dr. Robert E. Gutman at the annual meeting of the Society of Gynecologic Surgeons, showed that cure rates and patient satisfaction following pelvic prolapse repair were similar at three-year follow-up regardless of whether vaginal mesh or native tissue was used for the repair, according to the May 9, 2013, article in Ob.Gyn.News that reported on the study.* That article further reports that, “subjects treated with mesh had more complications without experiencing benefit beyond that observed in the native tissue repair patients.”

Read full story at PRWeb.com: Rottenstein Law Group LLP Acknowledges Study That Raises Questions About Use of Vaginal Mesh For Prolapse Repair

The post Rottenstein Law Group LLP Acknowledges Study That Raises Questions About Use of Vaginal Mesh For Prolapse Repair appeared first on Oregon Capitol News.

Elizabeth Childress was prescribed Byetta in January 2007 to treat her type 2 diabetes, and continued to take it through August of that year, according to court documents. In May 2011 she was diagnosed with thyroid cancer and attributes it to her use of Byetta, a drug that has also been linked to both thyroid cancer and pancreatic cancer in women.* Childress alleges that the drug makers were aware of the risks but did not notify patients of them.

“It is important that the drug makers are held accountable, if the allegations are true,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP.

Read more: Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports

The post Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports appeared first on Oregon Capitol News.

(PRWEB) May 09, 2013

For the first time in 55 years, spending on medications in the United States has dropped, in part because of patent expirations for popular drugs such as Lipitor.* The Rottenstein Law Group LLP, a Lipitor law firm, offers its opinion on what this means for those who seek to file Lipitor lawsuits because they suffered from Lipitor-induced diabetes.

Pfizer lost patent protection for Lipitor in 2011, which led to other manufacturers’ selling cheaper generic versions of the drug. Given the great number of Lipitor users, that switch to generic plays a large role in reduced spending, according to a May 9 Reuters report.

Read more: Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP

The post Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP appeared first on Oregon Capitol News.

(PRWEB) May 13, 2013

The popular statin Lipitor has been the focus of a number of research studies, some of which have found a possible link between the drug and an increased risk of type 2 diabetes in women who use Lipitor to help lower their cholesterol levels, according to Reuters.* The Rottenstein Law Group LLP, a Lipitor law firm, offers its opinion on what the studies mean for those who have suffered from diabetes allegedly caused by Lipitor and who wish to file a Lipitor lawsuit.

A 2011 study published in the Journal of the American College of Cardiology found that those at risk of getting diabetes were more likely to be diagnosed with the disease when they were using Lipitor, a statin prescribed to reduce high cholesterol in patients, according to Reuters. Another study, published in the January 2012 edition of JAMA: Internal Medicine, indicated that there is a potential link between statins and a type 2 diabetes risk in women.

Read more: Lipitor Lawsuit News: Rottenstein Law Group LLP Comments on Lipitor’s Possible Link to Diabetes Risk

The post Lipitor Lawsuit News: Rottenstein Law Group LLP Comments on Lipitor’s Possible Link to Diabetes Risk appeared first on Oregon Capitol News.

(PRWEB) May 06, 2013

Two weeks after a judge threw out seven bellwether NuvaRing lawsuits, plaintiffs scored a win on May 3 in the New Jersey multicounty litigation consolidation when a judge refused to dismiss punitive damages claims in nine bellwether NuvaRing lawsuits, according to court documents. The Rottenstein Law Group, a NuvaRing law firm, offers its opinion on the developments and notes that it operates a case information site that features a comprehensive history of the contraceptive device, in addition to how to go about filing a lawsuit.

Attorneys for medical device manufacturers Merck and Organon USA argued that punitive damages could not be sought in New Jersey because the state’s Product Liability Act excludes punitive damages in prescription drug litigation, according to court documents in In re: NuvaRing Litigation (BER-L-3081-09, Superior Court of New Jersey, Bergen County). Judge Brian R. Martinotti said the cases are primarily concerned with what the companies revealed to the plaintiffs and their doctors in each of the respective states—not what was disclosed to the U.S. Food and Drug Administration in warning labels issued from the companies’ headquarters in New Jersey. This, he said, meant that each of those respective states had an interest in regulating punitive damages differently.

Read more:  NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims 

The post NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims appeared first on Oregon Capitol News.

The most common side effects reported to the FDA include the expulsion of the device and the device dislocation (migration), according to a recent AdverseEvents Report. This is supported by a 2008 FDA report that mentions those alleged side effects, in addition to perforation of the uterine wall and pelvic inflammatory disease as primary potential issues.

“We file Mirena lawsuits daily for those who believe their intrauterine devices have harmed them,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “These reports could be valuable evidence for Mirena plaintiffs during trials.”

Read full story at PRWeb.com: Mirena IUD Lawsuit Update: Rottenstein Law Group Responds to FDA’s 47,000 Mirena Adverse Events Reports

The post Mirena IUD Lawsuit Update: Rottenstein Law Group Responds to FDA’s 47,000 Mirena Adverse Events Reports appeared first on Oregon Capitol News.

A federal judge recently issued an order postponing the second federal DePuy ASR bellwether trial from July to September, according to court documents. The Rottenstein Law Group, which offers information about the ASR hip implant and provides news updates on the product at http://www.depuyrecallnewscenter.com/lawsuits, offers insight into what this means for those looking to file DePuy lawsuits.

Judge David Katz issued the order on April 22, three days after the first ASR bellwether trial was pushed back from May to June, according to court documents in MDL-2197, U.S. District Court for the Northern District of Ohio.

“Delays can happen,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “This does not mean that those who seek to file hip implant lawsuits should be concerned about retaining an attorney for alleged harms such as metal poisoning, pain and discomfort. Every victim can have his or her day in court if he or she wants it.”

Read full story at PRWeb.com: DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial

The post DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial appeared first on Oregon Capitol News.